Deals Pages – CapitalXchange

Deals Pages – CapitalXchange https://capx.cooley.com Legal insight for the capital markets Mon, 02 Feb 2026 18:55:33 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.4 https://capx.cooley.com/wp-content/uploads/2025/08/cropped-pattern-wide-13-blue-32x32.png Deals Pages – CapitalXchange https://capx.cooley.com 32 32 238415165 Stubhub on its $800 Million IPO https://capx.cooley.com/deals/stubhub-on-its-800-million-ipo/ Thu, 30 Oct 2025 17:16:02 +0000 https://capx.cooley.com/?post_type=deals&p=3312 Cooley advised the underwriters of StubHub Holdings, a global secondary ticketing marketplace for live events, in connection with StubHub’s $800 million initial public offering (IPO). Partners David Peinsipp, Kristin VanderPas and Denny Won led the Cooley team advising the underwriters.

]]>

3312

LB Pharmaceuticals on its $285 Million IPO https://capx.cooley.com/deals/lb-pharmaceuticals-on-its-285-million-ipo/ Thu, 30 Oct 2025 17:14:54 +0000 https://capx.cooley.com/?post_type=deals&p=3309 Cooley advised LB Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel therapies for the treatment of neuropsychiatric diseases including schizophrenia, on its $285 million upsized initial public offering (IPO). Lawyers Brandon Fenn, Divakar Gupta, Marc Recht, Minkyu Park, Denny Xu, Danbi Kim, Ariane Andrade, Nathaniel Hearn and Karun Ahuja led the Cooley team advising LB…

Source

]]>

3309

Heartflow on its $364.2 Million Upsized IPO https://capx.cooley.com/deals/heartflow-on-its-167-million-upsized-ipo/ Thu, 30 Oct 2025 17:13:15 +0000 https://capx.cooley.com/?post_type=deals&p=3307 Cooley advised the underwriters of Heartflow, a leader in artificial intelligence technology for coronary artery disease, in connection with Heartflow’s $364.2 million upsized initial public offering (IPO). Partners David Peinsipp, Kristin VanderPas, Charlie Kim and Denny Won led the Cooley team advising the underwriters.

]]>

3307

Ambiq Micro on its $110.4 Million IPO https://capx.cooley.com/deals/ambiq-micro-on-its-110-4-million-ipo/ Thu, 30 Oct 2025 17:11:43 +0000 https://capx.cooley.com/?post_type=deals&p=3305 Cooley advised Ambiq Micro, a technology leader in ultra-low-power semiconductor solutions for edge artificial intelligence, on its $110.4 million initial public offering (IPO). Lawyers Christina Roupas, Courtney Tygesson, Michael Platt, Kelly Bartling and Grady Chang led the Cooley team advising Ambiq.

Source

]]>

3305

Caris Life Sciences on its $494 Million IPO https://capx.cooley.com/deals/caris-life-sciences-on-its-494-million-ipo/ Thu, 30 Oct 2025 17:09:51 +0000 https://capx.cooley.com/?post_type=deals&p=3301 Cooley advised the underwriters of Caris Life Sciences, a patient-centric, next-generation artificial intelligence techbio company and precision medicine pioneer, in connection with Caris’ $494 million initial public offering (IPO).

]]>

3301

AIRO Group on its $69 Million IPO https://capx.cooley.com/deals/airo-group-on-its-69-million-ipo/ Thu, 30 Oct 2025 16:55:31 +0000 https://capx.cooley.com/?post_type=deals&p=3299 Cooley advised AIRO Group Holdings, a company specializing in advanced aerospace and defense technologies, on its $69 million initial public offering (IPO). Lawyers Christina Roupas, Yvan-Claude Pierre, Courtney Tygesson and Grady Chang led the Cooley team advising AIRO.

Source

]]>

3299

Beta Bionics on its $234.6 Million IPO https://capx.cooley.com/deals/beta-bionics-on-its-234-6-million-ipo/ Thu, 30 Oct 2025 16:41:51 +0000 https://capx.cooley.com/?post_type=deals&p=3297 Cooley advised Beta Bionics, a pioneering leader in the development of advanced diabetes management solutions, on its upsized $234.6 million initial public offering (IPO) and concurrent $17 million private placement. Partners Carlos Ramirez, Mark Weeks and Charlie Kim led the Cooley team advising Beta Bionics. …

]]>

3297

Artiva Biotherapeutics on its $167 Million IPO https://capx.cooley.com/deals/artiva-biotherapeutics-on-its-167-million-ipo/ Wed, 11 Sep 2024 17:50:21 +0000 https://capx.cooley.com/?post_type=deals&p=2912 Cooley advised Artiva Biotherapeutics, a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, on its upsized $167 million initial public offering. Partners Carlos Ramirez and Charlie Kim led the Cooley team advising Artiva.

]]>

2912

Tempus AI on its $410.7 Million IPO https://capx.cooley.com/deals/tempus-ai-on-its-410-7-million-ipo/ Wed, 11 Sep 2024 17:48:46 +0000 https://capx.cooley.com/?post_type=deals&p=2909 Cooley advised Tempus AI, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, on its $410.7 million initial public offering. Chicago partners Christina Roupas and Courtney Tygesson led the Cooley team, which also included Richard Segal and Eric Jensen.

]]>

2909

Life360 on its $178.5 Million IPO https://capx.cooley.com/deals/life360-on-its-178-5-million-ipo/ Wed, 11 Sep 2024 17:46:38 +0000 https://capx.cooley.com/?post_type=deals&p=2906 Cooley advised Life360, a family connection and safety company, on its $178.5 million initial public offering. Lawyers Thomas Hopkins, David Peinsipp, Siana Lowrey, Natalie Karam and Alexander Gefter led the Cooley team advising Life360.

]]>

2906

Rubrik on its $752 Million IPO https://capx.cooley.com/deals/rubrik-on-its-752-million-ipo/ Wed, 11 Sep 2024 17:43:20 +0000 https://capx.cooley.com/?post_type=deals&p=2901 Cooley advised Rubrik, the Zero Trust Data Security Company delivering data security and operational resilience for enterprises, on its $752 million initial public offering. Partners Jon Avina, Calise Cheng and Milson Yu led the Cooley team advising Rubrik.

]]>

2901

Rapport Therapeutics on its $154 Million IPO https://capx.cooley.com/deals/rapport-therapeutics-on-its-154-million-ipo/ Wed, 11 Sep 2024 17:29:21 +0000 https://capx.cooley.com/?post_type=deals&p=2897 Cooley advised the underwriters in Rapport Therapeutics’ $154 million initial public offering. Partners Richard Segal, Divakar Gupta, Darah Protas and Ryan Sansom led the Cooley team. Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformational precision neuromedicines for patients suffering from central nervous system disorders.

]]>

2897

Boundless Bio on its $100 Million IPO https://capx.cooley.com/deals/boundless-bio-on-its-100-million-ipo/ Wed, 11 Sep 2024 17:24:27 +0000 https://capx.cooley.com/?post_type=deals&p=2894 Cooley advised the underwriters in Boundless Bio’s $100 million initial public offering. Partners Charlie Kim, Denny Won and Charles Bair led the Cooley team. Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics to address the significant unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA).

]]>

2894

Alumis on its $250 Million IPO and Private Placement https://capx.cooley.com/deals/alumis-closes-259-million-series-c/ Thu, 13 Jun 2024 01:27:49 +0000 https://capitalxchange.wpengine.com/?post_type=ancillary&p=2851 Cooley advised Alumis, a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize outcomes and transform the lives of patients with immune-mediated diseases, on its $250 million initial public offering and private placement. Partners Dave Peinsipp, Kristin VanderPas and Lauren Creel led the Cooley team.

]]>

2851

Alto Neuroscience on its $147.9 Million IPO https://capx.cooley.com/deals/alto-neuroscience-on-its-147-9-million-ipo/ Wed, 12 Jun 2024 05:08:51 +0000 https://capitalxchange.wpengine.com/?post_type=ancillary&p=2856 Cooley advised Alto Neuroscience, a company redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and highly effective medicines and helping patients get better faster, on its $147.9 million initial public offering. Partners Div Gupta, Christina Roupas, Courtney Tygesson and Laurie Bauer led the Cooley team advising Alto.

]]>

2856

CG Oncology on its $437 Million IPO https://capx.cooley.com/deals/cg-oncology-on-its-437-million-ipo/ Tue, 11 Jun 2024 04:20:16 +0000 https://capitalxchange.wpengine.com/?post_type=ancillary&p=2860 Cooley advised the underwriters of CG Oncology, a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, on the pricing of its upsized $437 million initial public offering. Partners Charlie Kim, Denny Won, Kristin VanderPas and David Peinsipp led the Cooley team advising…

]]>

2860

CARGO Therapeutics on its $281.3 Million IPO https://capx.cooley.com/deals/cargo-therapeutics-on-its-281-3-million-ipo/ Fri, 08 Mar 2024 15:44:39 +0000 https://capxdeals.wordpress.com/?p=396 Cooley advised the underwriters on CARGO Therapeutics’ $281.3 million initial public offering. Partners Denny Won, Charlie Kim, Kristin VanderPas and Dave Peinsipp led the Cooley team advising the underwriters.

]]>

396

Lexeo Therapeutics on its $100 Million IPO https://capx.cooley.com/deals/lexeo-therapeutics-on-its-100-million-ipo/ Fri, 08 Mar 2024 15:41:29 +0000 https://capxdeals.wordpress.com/?p=392 Cooley advised Lexeo Therapeutics, a clinical-stage gene therapy company advancing gene therapy candidates for genetically defined cardiovascular diseases and a genetically defined subgroup of Alzheimer’s disease, on its approximately $100 million initial public offering. Partners Eric Blanchard, Peter Byrne and Div Gupta led the Cooley team advising Lexeo.

]]>

392

Abivax on its $235.8 Million IPO https://capx.cooley.com/deals/abivax-on-its-235-8-million-ipo/ Fri, 08 Mar 2024 15:39:28 +0000 https://capxdeals.wordpress.com/?p=388 Cooley advised Abivax, a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, on its $235.8 million initial public offering. Partners Div Gupta, Marc Recht, Ryan Sansom and Denny Won led the Cooley team.

]]>

388

Instacart on its $660 Million IPO https://capx.cooley.com/deals/instacart-on-its-660-million-ipo/ Fri, 13 Oct 2023 23:09:30 +0000 https://capxdeals.wordpress.com/?p=383 Cooley represented Instacart, the leading grocery technology company in North America, on its $660 million initial public offering. Partners Jon Avina, Rachel Proffitt, Jonie Kondracki and Milson Yu led the Cooley team advising Instacart.

]]>

383